ACOT9: A Potential Drug Target for Alzheimer's Disease (G23597)

Target Name: ACOT9

NCBI ID: G23597

ACOT9

ACOT9: A Potential Drug Target for Alzheimer's Disease

ACOT9 (Alzheimer's disease-associated protein 9) is a protein that is expressed in the brain and is associated with the development and progression of Alzheimer's disease. The protein is made by the brain and is found in high concentrations in the brain, making it a potential drug target or biomarker for the disease.

Recent studies have identified ACOT9 as a potential drug target for Alzheimer's disease. The protein is known to interact with several other proteins that are also involved in the development and progression of the disease. For example, studies have shown that ACOT9 interacts with the protein BACE1, which is a key regulator of the beta-amyloid protein that is thought to contribute to the development of Alzheimer's disease.

Additionally, ACOT9 has been shown to interact with the protein TREM2, which is involved in the production of neurotransmitters that are important for brain function. This interaction between ACOT9 and TREM2 suggests that the protein may be involved in the regulation of brain function and could be a potential drug target for Alzheimer's disease.

Another study has shown that ACOT9 is expressed in the brains of individuals with Alzheimer's disease and that the levels of the protein are significantly higher in the brains of individuals with the disease compared to those without the disease. This suggests that ACOT9 may be a useful biomarker for the disease and could be used to track the progression of the disease.

In addition to its potential as a drug target, ACOT9 is also a potential biomarker for Alzheimer's disease. The protein is known to be expressed in the brains of individuals with the disease and has been shown to be significantly higher in the brains of individuals with the disease compared to those without the disease. This suggests that ACOT9 may be a useful biomarker for the disease and could be used to track the progression of the disease.

In conclusion, ACOT9 is a protein that is associated with the development and progression of Alzheimer's disease and has been shown to interact with several other proteins that are also involved in the disease. As a result, ACOT9 is a potential drug target or biomarker for the disease. Further research is needed to fully understand the role of ACOT9 in the development and progression of Alzheimer's disease.

Protein Name: Acyl-CoA Thioesterase 9

Functions: Acyl-CoA thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH), providing the potential to regulate intracellular levels of acyl-CoAs, free fatty acids and CoASH. Active on long chain acyl-CoAs

The "ACOT9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACOT9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets